CLINICAL TRIAL RECRUITMENT — THE CONSENT PROBLEM
TrialSpark’s stated model was “unlocking the 98% of patients who have never been exposed to trials” by embedding its own certified research coordinators inside independent doctor practices, turning routine medical offices into clinical trial sites through financial arrangements with physicians. The patient believes they are receiving care from their doctor; the doctor’s practice has a revenue relationship with the trial company. This structural conflict of interest is compounded by the populations these trial sites concentrate in: registered agent addresses for TrialSpark co-located with BOLD, Inc. (care for adults with intellectual and developmental disabilities — people who often cannot consent for themselves) and the Alzheimer’s Association (dementia patients who progressively lose capacity to consent). The mobile phlebotomy arm (Speedy Sticks) extends blood draw access into nursing homes and private residences where patients are physically isolated from independent advocates. After rebranding from TrialSpark to Formation Bio in December 2023, the company shifted from operating dozens of its own branded trial sites to running trials through subsidiary clinics capable of performing invasive procedures including lumbar punctures — distancing the parent company’s name from the clinical interface while maintaining the same patient access pipeline. The pattern is consistent across the network: UBI cash studies target low-income communities in rural West Virginia, eastern North Carolina, and the Mississippi Delta; Worldcoin collects iris scans from villagers in Africa and Southeast Asia for $50 in crypto tokens; Watsi funds surgeries in 25 developing nations. In every case, the populations targeted are those least equipped to refuse participation, question data collection practices, or pursue legal recourse — and most likely to accept whatever is offered because the alternative is nothing.
The United States already spends more than enough money to provide universal healthcare. The barrier is not total national affordability; it is that healthcare spending is routed through fragmented private billing, employer dependence, state eligibility gates, and profit-seeking intermediaries instead of a universal care floor.
Path to Redemption
Basic healthcare access first
Patients must be able to see doctors outside employment, wealth, or trial enrollment.
Doctor-referral-only trial entry
Experimental treatment is offered through an independent treating clinician after documented standard-care failure or justified urgency.
No cash inducement for participation
Trial participation cannot be made financially attractive to desperation. The benefit is medical access, monitoring, follow-up, and care — not payment.
Condition-scaled trial size
Trial enrollment requirements scale with rarity, severity, available alternatives, prior evidence, predicted risk, and population-level harm reduction.
No default healthy-volunteer exposure
Therapeutic drugs should be tested in the population with medical need unless a specific ethical/scientific justification exists.
AI as risk-reduction, not consent-replacement
AI may support molecular risk prediction, trial design, monitoring, and matching, but cannot replace FDA review, clinician judgment, IRB oversight, or patient consent.
Dropout data included
Withdrawal reasons and end-of-study follow-up surveys become part of safety and efficacy analysis, not discarded noise.
Mandatory clinical-trial injury insurance
Before human dosing, sponsors must carry insurance sufficient to cover lifelong harm, with premiums reflecting risk and no shell-company escape hatch.
Post-trial access bridge
Participants who benefit receive guaranteed access through approval/ramp-up, then transition into ordinary healthcare coverage.
Public-interest data layer
Outcomes, adverse events, dropout reasons, and trial design data should be publicly reviewable enough to prevent proprietary concealment of safety signals.